CT-0508 is under clinical development by Carisma Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CT-0508’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CT-0508 is under development for the treatment of HER2-positive solid tumors including ovarian cancer, breast cancer, peritoneal cancer, gastric cancer and gastroesophageal junction cancer. It is developed based on the CARMA platform that combines chimeric antigen receptor targeting with macrophages to tackle solid tumors. The drug candidate is genetically engineered adenovirus (Ad5f35) -transduced anti-HER2 CAR. It is administered through intravenous and intraperitoneal route.
Carisma Therapeutics overview
Carisma Therapeutics is a biotechnology service provider that discovers and develops macrophage-based immunotherapeutic for the treatment of cancer. The company product CAR-macrophage platform to provide human macrophages the capability to identify relevant targets to exterminate cancer cells in solid tumors. Carisma Therapeutics technology harnesses the latest developments in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy to treat multiple diseases in humans. Its portfolio includes CT – 0508 (HER2), CT – 1119 (Mesothelin), CT – 0729 (PSMA) which treat mesothelin-positive solid tumors, prostate cancer, neurodegeneration, liver fibrosis and others. Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania, the US.
For a complete picture of CT-0508’s drug-specific PTSR and LoA scores, buy the report here.